Anika Therapeutics, Inc. (ANIK) Tops Q2 EPS by 3c, Revenue Light
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $21.11 +1.15%
Revenue Growth %: +5.5%
Financial Fact:
Diluted weighted average common shares outstanding: 15.08M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Revenue Growth %: +5.5%
Financial Fact:
Diluted weighted average common shares outstanding: 15.08M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Join SI Premium – FREE
Anika Therapeutics, Inc. (NASDAQ: ANIK) reported Q2 EPS of $0.60, $0.03 better than the analyst estimate of $0.57. Revenue for the quarter came in at $26.3 million versus the consensus estimate of $28.2 million.
For earnings history and earnings-related data on Anika Therapeutics, Inc. (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
- Everus Construction Group acquires Epsilon Industries for $295M
- Stifel Starts Tower Semiconductor (TSEM) at Buy, Top Pick
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
